Previous 10 | Next 10 |
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that its first-quarter 2020 financial results will be released on Wednesday, May 6, 2020. Following the announcement, Horizon's management will host a live webcast at 8 a.m. Eastern Time to review the Company's financial and operating re...
New York City, NY: April 09, 2020 – Recent Research and Future Market Potential of Automatic Floor Cleaning Machines Market in Global Industry: 2020 Research and New Innovations in Machines Sector. The prime objective of the report is to offer updates and information related to future ...
Horizon Therapeutics plc (NASDAQ:HZNP) today announced it has been selected as one of the 2020 Best Workplaces in Health Care and Biopharma by Fortune and Great Place to Work®. "Providing meaningful support for our employees is always paramount, which is why we take special pride...
The stocks of drug developers can rise and fall on the release of clinical trial results, particularly if they are for the company's most advanced drug in development. When the results are positive, the stock will typically shoot up on the optimism, and bad news from the clinic can tank a stock....
Horizon Therapeutics ( HZNP -0.6% ) has acquired San Diego, CA-based Curzion Pharmaceuticals, the developer of an oral selective lysophosphatidic acid 1 receptor (LPAR 1 ) antagonist called CZN001 (renamed HZN-825) for the potential treatment of diffuse cutaneous systemic sclerosis , a ...
-- Gained Rights to Product Candidate, CZN001 (renamed HZN-825), a Potential Treatment for Diffuse Cutaneous Systemic Sclerosis; a Rare Rheumatic Disease with No FDA-Approved Treatment -- -- Compelling Fit with Horizon’s Strategy to Acquire and Develop Medicines Targeting Diseas...
-- Data presented as part of ENDO 2020 demonstrates proptosis response regardless of age, gender and smoking status -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced new pooled efficacy data from the Phase 2 and 3 clinical trials of TEPEZZA™ (teprotumumab-trbw) showing ...
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it, in partnership with Illinois Governor JB Pritzker, has provided $500,000 to the Illinois COVID-19 Response Fund and $500,000 to the Illinois Biotechnology Innovation Organization (iBIO) Institute’s COVID-19 Response Fund....
On March 18th Acer Therapeutics ( ACER ) announced that the FDA's Office of New Drugs (OND) denied Acer's appeal of the Complete Response Letter ("CRL") received last June in relation to Acer's New Drug Application (NDA) for EDSIVO™ for the treatment of patients with vascular Ehlers-D...
Today, we will see why Genmab (GMAB) is an attractive biotech pick in March 2020. Company overview Genmab is a dual-listed biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. The company was founded in 19...
News, Short Squeeze, Breakout and More Instantly...
Horizon Therapeutics Public Limited Company Company Name:
HZNP Stock Symbol:
NASDAQ Market:
Horizon Therapeutics Public Limited Company Website:
Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...
Horizon Therapeutics Public Limited Company (HZNP) is expected to report $1.22 for Q3 2023
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE October 6, 2023 RECOM...